Marginal Zone Lymphoma

  • Birgit BurkhardtEmail author


Data on clinical features, treatment, and outcome of pediatric marginal zone lymphoma (MZL) is still limited. MZL represent a B-NHL subtype which clearly differs from aggressive B-NHL with respect to clinical presentation and the need of treatment intensity. Three subtypes of MZL are defined with nodal MZL (nMZL), extranodal MZL (enMZL), and splenic MZL. The latter subtype is rare in children and adolescents. Nodal MZL occur most commonly in healthy male adolescents and present with limited stage disease. Extra nodal MZL are also most common in the adolescent age group with a less prominent male predominance compared with nMZL. An association with infectious agents, inflammation, autoimmune diseases, and immunodeficiency is observed in enMZL. One third of patients presents with advanced stage of disease. For both nMZL and enMZL, the prognosis is excellent with limited treatment for the vast majority of patients.


Marginal zone lymphoma Pediatric Adolescents Treatment Outcome 


  1. 1.
    Swerdlow SH, et al. WHO classification of tumors of hematopoietic and lymphoid tissues. 4th ed. Lyon: IARC Press; 2008.Google Scholar
  2. 2.
    Swerdlow SH, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–90.PubMedPubMedCentralGoogle Scholar
  3. 3.
    Zinzani PL. The many faces of marginal zone lymphoma. Hematology Am Soc Hematol Educ Program. 2012;2012:426–32.PubMedGoogle Scholar
  4. 4.
    Ronceray L, et al. Children and adolescents with marginal zone lymphoma have an excellent prognosis with limited chemotherapy or a watch-and-wait strategy after complete resection. Pediatr Blood Cancer. 2018;65(4).Google Scholar
  5. 5.
    Makarova O, et al. Excellent outcome with limited treatment in paediatric patients with marginal zone lymphoma. Br J Haematol. 2017;182(5):735–9.PubMedGoogle Scholar
  6. 6.
    Amitay-Laish I, et al. Paediatric primary cutaneous marginal zone B-cell lymphoma: does it differ from its adult counterpart? Br J Dermatol. 2017;176(4):1010–20.PubMedGoogle Scholar
  7. 7.
    Collado P, et al. Extranodal marginal zone B cell lymphoma: an unexpected complication in children with Sjogren’s syndrome. Reumatol Clin. 2018;14(4):227–9.PubMedGoogle Scholar
  8. 8.
    Hori D, et al. Pediatric nodal marginal zone lymphoma in a Japanese boy. Pediatr Int. 2017;59(3):358–60.PubMedGoogle Scholar
  9. 9.
    O’Suoji C, et al. Rare pediatric Non-Hodgkin lymphomas: a report from Children’s Oncology Group Study ANHL 04B1. Pediatr Blood Cancer. 2016;63(5):794–800.PubMedGoogle Scholar
  10. 10.
    Ozawa MG, et al. A study of the mutational landscape of pediatric-type follicular lymphoma and pediatric nodal marginal zone lymphoma. Mod Pathol. 2016;29(10):1212–20.PubMedPubMedCentralGoogle Scholar
  11. 11.
    Lum SH, et al. Successful curative therapy with rituximab and allogeneic haematopoietic stem cell transplantation for MALT lymphoma associated With STK4-mutated CD4+ lymphocytopenia. Pediatr Blood Cancer. 2016;63(9):1657–9.PubMedGoogle Scholar
  12. 12.
    Gabali A, et al. Pediatric extranodal marginal zone B-cell lymphoma presenting as amyloidosis in minor salivary glands: a case report and review of the literature. J Pediatr Hematol Oncol. 2013;35(3):e130–3.PubMedGoogle Scholar
  13. 13.
    Rizzo KA, et al. Marginal zone lymphomas in children and the young adult population; characterization of genetic aberrations by FISH and RT-PCR. Mod Pathol. 2010;23(6):866–73.PubMedPubMedCentralGoogle Scholar
  14. 14.
    Kempf W, et al. Primary cutaneous marginal zone lymphoma in children: a report of 3 cases and review of the literature. Am J Dermatopathol. 2014;36(8):661–6.PubMedGoogle Scholar
  15. 15.
    Ryu M, et al. Pediatric mucosa-associated lymphoid tissue (MALT) lymphoma of lip: a case report and literature review. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2009;107(3):393–7.PubMedGoogle Scholar
  16. 16.
    Claviez A, et al. MALT lymphoma in children: a report from the NHL-BFM Study Group. Pediatr Blood Cancer. 2006;47(2):210–4.PubMedGoogle Scholar
  17. 17.
    Mo JQ, et al. MALT lymphoma in children: case report and review of the literature. Pediatr Dev Pathol. 2004;7(4):407–13.PubMedGoogle Scholar
  18. 18.
    Taddesse-Heath L, et al. Marginal zone B-cell lymphoma in children and young adults. Am J Surg Pathol. 2003;27(4):522–31.PubMedPubMedCentralGoogle Scholar
  19. 19.
    van den Brand M, van Krieken JH. Recognizing nodal marginal zone lymphoma: recent advances and pitfalls. A systematic review. Haematologica. 2013;98(7):1003–13.PubMedPubMedCentralGoogle Scholar
  20. 20.
    Desai A, et al. Long-term course of patients with primary ocular adnexal MALT lymphoma: a large single-institution cohort study. Blood. 2017;129(3):324–32.PubMedGoogle Scholar
  21. 21.
    Hoh H, et al. MALT lymphoma of the conjunctiva in a 13-year old child--5-year relapse-free follow-up following antibiotic treatment. Klin Monatsbl Augenheilkd. 2016;233(1):79–84.PubMedGoogle Scholar
  22. 22.
    Park MY, et al. Pediatric primary cutaneous marginal zone B-cell lymphoma treated with intralesional rituximab. Eur J Dermatol. 2010;20(4):533–4.PubMedGoogle Scholar
  23. 23.
    Ghatalia P, et al. Primary cutaneous marginal zone lymphoma associated with juxta-articular fibrotic nodules in a teenager. J Cutan Pathol. 2013;40(5):477–84.PubMedGoogle Scholar
  24. 24.
    Berger F, et al. Non-MALT marginal zone B-cell lymphomas: a description of clinical presentation and outcome in 124 patients. Blood. 2000;95(6):1950–6.Google Scholar
  25. 25.
    Sovani V, et al. Bone marrow trephine biopsy involvement by lymphoma: review of histopathological features in 511 specimens and correlation with diagnostic biopsy, aspirate and peripheral blood findings. J Clin Pathol. 2014;67(5):389–95.PubMedGoogle Scholar
  26. 26.
    Mittal N, et al. A unique description of stage IV extranodal marginal zone lymphoma (EMZL) in an adolescent associated with gamma heavy chain disease. Pediatr Blood Cancer. 2015;62(5):905–8.PubMedGoogle Scholar
  27. 27.
    Hyjek E, Isaacson PG. Primary B cell lymphoma of the thyroid and its relationship to Hashimoto’s thyroiditis. Hum Pathol. 1988;19(11):1315–26.PubMedGoogle Scholar
  28. 28.
    Hyjek E, Smith WJ, Isaacson PG. Primary B-cell lymphoma of salivary glands and its relationship to myoepithelial sialadenitis. Hum Pathol. 1988;19(7):766–76.PubMedGoogle Scholar
  29. 29.
    Suarez F, et al. Infection-associated lymphomas derived from marginal zone B cells: a model of antigen-driven lymphoproliferation. Blood. 2006;107(8):3034–44.PubMedGoogle Scholar
  30. 30.
    Perrone S, et al. Infectious aetiology of marginal zone lymphoma and role of anti-infective therapy. Mediterr J Hematol Infect Dis. 2016;8(1):e2016006.PubMedPubMedCentralGoogle Scholar
  31. 31.
    Ekstrom Smedby K, et al. Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium. Blood. 2008;111(8):4029–38.PubMedPubMedCentralGoogle Scholar
  32. 32.
    Ferreri AJ, Govi S, Ponzoni M. Marginal zone lymphomas and infectious agents. Semin Cancer Biol. 2013;23(6):431–40.PubMedGoogle Scholar
  33. 33.
    Morgner A, et al. Malignant tumors of the stomach. Gastric mucosa-associated lymphoid tissue lymphoma and Helicobacter pylori. Gastroenterol Clin N Am. 2000;29(3):593–607.Google Scholar
  34. 34.
    Kluin PM, et al. Paediatric nodal marginal zone B-cell lymphadenopathy of the neck: a Haemophilus influenzae-driven immune disorder? J Pathol. 2015;236(3):302–14.PubMedGoogle Scholar
  35. 35.
    Bata BM, et al. Combined intraocular and systemic rituximab for ocular lymphoproliferative disorder with extranodal marginal zone lymphoma-type morphology after heart transplant. J AAPOS. 2018;22(2):159–61.PubMedGoogle Scholar
  36. 36.
    Gibson SE, et al. EBV-positive extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue in the posttransplant setting: a distinct type of posttransplant lymphoproliferative disorder? Am J Surg Pathol. 2011;35(6):807–15.PubMedGoogle Scholar
  37. 37.
    Aghamohammadi A, et al. Lymphoma of mucosa-associated lymphoid tissue in common variable immunodeficiency. Leuk Lymphoma. 2006;47(2):343–6.PubMedGoogle Scholar
  38. 38.
    Koo M, Ohgami RS. Pediatric-type follicular lymphoma and pediatric nodal marginal zone lymphoma: recent clinical, morphologic, immunophenotypic, and genetic insights. Adv Anat Pathol. 2017;24(3):128–35.PubMedGoogle Scholar
  39. 39.
    Maeshima AM, et al. Clinicopathological features of histological transformation from extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue to diffuse large B-cell lymphoma: an analysis of 467 patients. Br J Haematol. 2016;174(6):923–31.PubMedGoogle Scholar
  40. 40.
    Attygalle AD, et al. Atypical marginal zone hyperplasia of mucosa-associated lymphoid tissue: a reactive condition of childhood showing immunoglobulin lambda light-chain restriction. Blood. 2004;104(10):3343–8.PubMedGoogle Scholar
  41. 41.
    Caltharp SA, Qayed M, Park SI. Atypical marginal zone hyperplasia is a mimic for lymphoma in pediatric transplant recipients: report of two patients. Pediatr Dev Pathol. 2015;18(5):416–21.PubMedGoogle Scholar
  42. 42.
    Murphy SB. Classification, staging and end results of treatment of childhood non-Hodgkin’s lymphomas: dissimilarities from lymphomas in adults. Semin Oncol. 1980;7(3):332–9.PubMedPubMedCentralGoogle Scholar
  43. 43.
    Rosolen A, et al. Revised international pediatric Non-Hodgkin lymphoma staging system. J Clin Oncol. 2015;33(18):2112–8.PubMedPubMedCentralGoogle Scholar
  44. 44.
    Park JY, et al. Bone marrow involvement is rare in superficial gastric mucosa-associated lymphoid tissue lymphoma. Dig Liver Dis. 2016;48(1):81–6.PubMedGoogle Scholar
  45. 45.
    Ayanambakkam A, et al. Extranodal marginal zone lymphoma of the central nervous system. Clin Lymphoma Myeloma Leuk. 2018;18(1):34–37 e8.PubMedGoogle Scholar
  46. 46.
    Fujita N, et al. Results of the Japan Association of Childhood Leukemia Study (JACLS) NHL-98 protocol for the treatment of B-cell non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia in childhood. Leuk Lymphoma. 2011;52(2):223–9.PubMedGoogle Scholar
  47. 47.
    Gerrard M, et al. Excellent survival following two courses of COPAD chemotherapy in children and adolescents with resected localized B-cell non-Hodgkin’s lymphoma: results of the FAB/LMB 96 international study. Br J Haematol. 2008;141(6):840–7.Google Scholar
  48. 48.
    Goldman S, et al. Rituximab and FAB/LMB 96 chemotherapy in children with Stage III/IV B-cell non-Hodgkin lymphoma: a Children’s Oncology Group report. Leukemia. 2013;27(5):1174–7.Google Scholar
  49. 49.
    Woessmann W, et al. The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95. Blood. 2005;105(3):948–58.PubMedPubMedCentralGoogle Scholar
  50. 50.
    Wirth A, et al. Long-term outcome for gastric marginal zone lymphoma treated with radiotherapy: a retrospective, multi-centre, International Extranodal Lymphoma Study Group study. Ann Oncol. 2013;24(5):1344–51.PubMedGoogle Scholar
  51. 51.
    Nam TK, et al. The role of radiotherapy in the treatment of gastric mucosa-associated lymphoid tissue lymphoma. Cancer Res Treat. 2014;46(1):33–40.PubMedPubMedCentralGoogle Scholar
  52. 52.
    Olszewski AJ, Desai A. Radiation therapy administration and survival in stage I/II extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. Int J Radiat Oncol Biol Phys. 2014;88(3):642–9.PubMedGoogle Scholar
  53. 53.
    Ruskone-Fourmestraux A, et al. Exclusive moderate-dose radiotherapy in gastric marginal zone B-cell MALT lymphoma: results of a prospective study with a long term follow-up. Radiother Oncol. 2015;117(1):178–82.PubMedGoogle Scholar
  54. 54.
    Fabbri A, et al. Rituximab plus liposomal pegylated doxorubicin in the treatment of primary cutaneous B-cell lymphomas. Eur J Haematol. 2014;93(2):129–36.PubMedGoogle Scholar
  55. 55.
    Suarez AL, et al. Primary cutaneous B-cell lymphomas: part II. Therapy and future directions. J Am Acad Dermatol. 2013;69(3):343 e1–11; quiz 355-6.Google Scholar
  56. 56.
    Hamilton SN, et al. Treatment and outcomes in patients with primary cutaneous B-cell lymphoma: the BC Cancer Agency experience. Int J Radiat Oncol Biol Phys. 2013;87(4):719–25.PubMedGoogle Scholar
  57. 57.
    Specht L, et al. Modern radiation therapy for primary cutaneous lymphomas: field and dose guidelines from the International Lymphoma Radiation Oncology Group. Int J Radiat Oncol Biol Phys. 2015;92(1):32–9.PubMedGoogle Scholar
  58. 58.
    Vandersee S, et al. Treatment of indolent primary cutaneous B-cell lymphomas with subcutaneous interferon-alfa. J Am Acad Dermatol. 2014;70(4):709–15.PubMedGoogle Scholar
  59. 59.
    Wilcox RA. Cutaneous B-cell lymphomas: 2018 update on diagnosis, risk-stratification, and management. Am J Hematol. 2018;93: 1427–30.PubMedGoogle Scholar
  60. 60.
    Penate Y, et al. Intralesional rituximab in the treatment of indolent primary cutaneous B-cell lymphomas: an epidemiological observational multicentre study. The Spanish Working Group on Cutaneous Lymphoma. Br J Dermatol. 2012;167(1):174–9.PubMedGoogle Scholar
  61. 61.
    Kyrtsonis MC, et al. Favorable outcome of primary cutaneous marginal zone lymphoma treated with intralesional rituximab. Eur J Haematol. 2006;77(4):300–3.PubMedGoogle Scholar
  62. 62.
    Kerl K, et al. Intralesional and intravenous treatment of cutaneous B-cell lymphomas with the monoclonal anti-CD20 antibody rituximab: report and follow-up of eight cases. Br J Dermatol. 2006;155(6):1197–200.PubMedGoogle Scholar
  63. 63.
    Park HH, et al. Treatment outcome and risk analysis for cataract after radiotherapy of localized ocular adnexal mucosa-associated lymphoid tissue (MALT) lymphoma. Radiat Oncol J. 2017;35(3):249–56.PubMedPubMedCentralGoogle Scholar
  64. 64.
    Ferreri AJ, et al. Intralesional rituximab: a new therapeutic approach for patients with conjunctival lymphomas. Ophthalmology. 2011;118(1):24–8.PubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Pediatric Hematology and OncologyUniversity Hospital MünsterMünsterGermany

Personalised recommendations